In vitro activity of the ketolide ABT-773.
The in vitro activities of ABT-773, azithromycin, erythromycin, and clindamycin were compared by testing 1,223 clinical isolates selected to represent different species and phenotypes. ABT-773 was particularly potent against staphylococci (the MIC at which 90% of the strains tested were inhibited [MIC(90)] was < or =0.06 microg/ml), including all strains that were macrolide resistant but clindamycin susceptible. Streptococcus pneumoniae and other streptococci were inhibited by low concentrations of ABT-773, and that included most erythromycin-resistant strains. Against Haemophilus influenzae, ABT-773 and azithromycin were similar in their antibacterial potency (MIC(90), 4.0 and 2.0 microg/ml, respectively).
Barry
A L
AL
The Clinical Microbiology Institute, 9725 S.W. Commerce Circle, Wilsonville, OR 97070, USA. cmi@hevanet.com
Fuchs
P C
PC
Brown
S D
SD
D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D006193:Haemophilus influenzae / Q000187:drug effects*; D006801:Humans; D048628:Ketolides; D008826:Microbial Sensitivity Tests; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D048628:Ketolides; D004917:Erythromycin; C405499:cethromycin